Discover the portfolio of biological and biosimilar medicines produced and distributed for the entire population.
Medicine indicated to stimulate the production of white blood cells in the bone marrow, helping prevent infections in patients undergoing certain treatments, such as chemotherapy.
Medication indicated for the treatment of autoimmune diseases, such as Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis.
Medicine indicated for the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Medicine indicated for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis.
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels (angiogenesis). It is indicated for the treatment of several diseases, particularly various types of cancer, including: Metastatic colorectal cancer; Advanced or metastatic non-small cell lung cancer, Metastatic breast cancer; Metastatic kidney cancer (advanced renal cell carcinoma), Advanced or recurrent ovarian, fallopian tube, and primary peritoneal cancer; Persistent, recurrent or metastatic cervical cancer.
Medicine indicated for the treatment of non-Hodgkin’s lymphoma, chronic lymphoblastic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Medicine indicated for the treatment of early-stage breast cancer, metastatic and non-metastatic breast cancer, and advanced gastric cancer.
A Bionovis é pioneira na produção e comercialização de medicamentos biológicos e biossimilares.
Nossa busca por inovações científicas e medicamentos de alta complexidade visa construir um Brasil e um mundo mais saudável para todos.
© 2025 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
